Is adagrasib included in medical insurance?

Adagrasib (Adagrasib) is an oral small molecule inhibitor under development. The chemical name is{(2S)-4-[7-(8-chloronaphthalene-1-yl)-2-{[(2S) )-1-methylpyrrolidin-2-yl]-methoxy}-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl}acetonitrile, primarily used to treat certain forms of lung cancer, particularly those with driver KRAS G12C mutated non-small cell lung cancer.

KRAS G12C protein is an oncogenic driver. These hard-to-reach targets are known to be guanine nucleotide-dependent switches that control multiple signaling pathways responsible for cell growth and proliferation. When this protein mutates, cell function is altered, causing cells to continue to grow uncontrollably. It inhibits tumor growth by binding toKRAS G12C protein and preventing it from erroneously activating signaling pathways. It is an irreversibleKRAS G12C inhibitor that covalently binds to the mutated cysteine u200bu200bin KRAS G12C, locking the mutated protein and leaving it in an inactive state, thereby inhibiting its "turning on", thereby inhibiting tumor growth.

Sinceadagrasibthe original drug has not been launched in China and cannot be included in medical insurance, patients can only purchase adagrasib through overseas channels. The price of the original American version200mg*180 tablets per box is more than 100,000 yuan (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.